Medicine and Dentistry
Systemic Scleroderma
100%
Pulmonary Hypertension
71%
Endothelin 1
42%
Therapeutic Procedure
42%
Diseases
28%
Development
28%
Blood Vessel Injury
28%
Bosentan
28%
Patient
28%
Inpatient
28%
Morbidity
14%
Complication
14%
Combination Therapy
14%
Pathophysiology
14%
Autoimmune Disease
14%
Evaluation Study
14%
Receptor Blocking Agent
14%
Pulmonary Fibrosis
14%
Mortality
14%
Finger Ulcer
14%
Vascular Fibrosis
14%
Recognition
14%
Organ
14%
Pharmacology, Toxicology and Pharmaceutical Science
Systemic Sclerosis
100%
Pulmonary Hypertension
71%
Endothelin 1
42%
Diseases
28%
Blood Vessel Injury
28%
Bosentan
28%
Complication
14%
Morbidity
14%
Receptor Blocking Agent
14%
Pathophysiology
14%
Autoimmune Disease
14%
Mortality
14%
Lung Fibrosis
14%
Vascular Fibrosis
14%
Finger Ulcer
14%
INIS
hypertension
71%
patients
57%
diseases
42%
endothelins
42%
management
28%
fibrosis
28%
damage
28%
evaluation
14%
therapy
14%
organs
14%
production
14%
reviews
14%
mortality
14%
receptors
14%
morbidity
14%
ulcers
14%